RxDoctor Payments DataLook up a doctor →

Antonious Attallah, MD

Interventional Cardiology · Roseville, MINPI 1306081138

Payments from drug & device makers

$260,946in general payments, 2019–2025

Across 372 payments — averaging $701.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$139K
  • Shockwave Medical, Inc$33K
  • Boston Scientific$30K
  • E.r. Squibb & Sons, L.L.C.$24K
  • EKOS Corporation$18K
  • Chiesi USA, Inc.$9K
  • plus $7K from 30 others

What the payments were for

  • Consulting fees$9,4509%
  • Speaking & faculty fees$72,24172%
  • Travel & lodging$8,6689%
  • Food & beverage$9,4749%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$260,946 in reported general payments places this provider in the 85th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$139,070
Medicare patients
575
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis14$331,849
EliquisApixaban251$215,187
EntrestoSacubitril/Valsartan135$132,695
FarxigaDapagliflozin Propanediol107$108,261
Repatha SureclickEvolocumab75$70,325
JardianceEmpagliflozin67$59,607
XareltoRivaroxaban77$56,887
BrilintaTicagrelor41$27,220
Praluent PenAlirocumab13$16,782
Rosuvastatin Calcium591$11,036
Metoprolol Succinate376$6,399
ClopidogrelClopidogrel Bisulfate354$6,325
Nifedipine ErNifedipine132$4,611
Carvedilol406$3,501
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$2,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$31$547,036265 claims
NovartisEntresto$277$132,695135 claims
Boehringer IngelheimJardiance$14$59,60767 claims
Johnson & JohnsonXarelto$88$56,88777 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →